secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001438533-26-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere reports Q4 net income of $2.7M; FILSPARI sales up 108% YoY to $103.3M
-----------------------------------------------------------------------------

- FILSPARI U.S. net product sales $103.3M in Q4 2025 (+108% YoY); full year $322M (+144%).
- Q4 GAAP net income $2.7M ($0.03/share) vs net loss $60.3M in Q4 2024; non-GAAP net income $33.3M.
- PDUFA target for FILSPARI in FSGS is April 13, 2026; commercial launch preparations ongoing.
- Cash & securities $322.8M at Dec 31, 2025; expects $25M milestone from Mirum in H1 2026.
- Phase 3 HARMONY study of pegtibatinase in HCU resumed enrollment; primary endpoint tHcy change.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/0001438533-26-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/tvtx-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001438533-26-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer